我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
29
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1985
已完成
24
82.8%
终止
4
13.8%
撤回
1
3.5%
暂无批准数据
- Novartis' eye care division Alcon receives positive CHMP opinion for Jetrea (ocriplasmin) to treat vitreomacular traction and associated macular holes in European patients. - The innovative treatment addresses an unmet need for 250,000-300,000 European patients with VMT, offering an alternative to the current 'watchful waiting' approach before late-stage surgery. - Following FDA approval in October 2012, Europe is set to become the first region outside the US to approve Jetrea, marking a significant advancement in retinal therapy.
